BridgeBio Pharma, Inc. (BBIO) Competitors & Peers
The 5 largest companies in the same industry as BridgeBio Pharma, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $508.35 | P/E 29.8RSI 43Cap 130.0 B |
| REGN | Peer | $784.52 | P/E 19.4RSI 46Cap 80.6 B |
| ARGX | Peer | $997.60 | P/E 38.0RSI 53Cap 62.1 B |
| RVMD | Peer | $192.88 | RSI 42Cap 42.5 B |
| CSLLY | Peer | $30.86 | P/E 18.2RSI 71Cap 60.1 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- BAYRYSupplier
Own 10-Q customer-concentration disclosure: BayerConsumerCareAG = 60% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - LIANYSupplier
Own 10-K customer-concentration disclosure: LianBio = 14% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - 4151.TSupplier
Own 10-Q customer-concentration disclosure: KyowaKirinCo.Ltd = 75% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - BAYN.DESupplier
Own 10-Q customer-concentration disclosure: Bayer = 20% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- ALNYCompetitor
BridgeBio's acoramidis competes with Alnylam's RNAi drugs for amyloidosis treatment.
Model-inferred, unverified — treat as a lead, not evidence